Loss of STAT1 from mouse mammary epithelium results in an increased Neu-induced tumor burden.

Type I and type II classes of interferons (IFNs) signal through the JAK/STAT1 pathway and are known to be important in adaptive and innate immune responses and in protection against tumors. Although STAT1 is widely considered a tumor suppressor, it remains unclear, however, if this function occurs in tumor cells (cell autonomous) or if STAT1 acts primarily through immune cells. Here, the question of whether STAT1 has a cell autonomous role in mammary tumor formation was addressed in a mouse model of ERBB2/neu-induced breast cancer in the absence and presence of STAT1. For this purpose, mice that carry floxed Stat1 alleles, which permit cell-specific removal of STAT1, were generated. To induce tumors only in mammary cells lacking STAT1, Stat1 floxed mice were crossed with transgenic mice that express cre recombinase and the neu oncogene under the mouse mammary tumor virus LTR (Stat1fl/fl NIC). Stat1 was effectively deleted in mammary epithelium of virgin Stat1fl/fl NIC females. Time-to-tumor onset was significantly shorter in Stat1fl/fl NIC females than in WT NIC (Wilcoxon rank sum test, P = .02). The median time-to-tumor onset in the Stat1fl/fl NIC mice was 49.4 weeks, whereas it was 62.4 weeks in the WT NIC mice. These results suggest that STAT1 in mammary epithelial cells may play a role in suppressing tumorigenesis. The Stat1 floxed allele described in this study is also a unique resource to determine the cellular targets of IFNs and STAT1 action, which should aid our understanding and appreciation of these pathways.

[1]  T. Pawson,et al.  ShcA signalling is essential for tumour progression in mouse models of human breast cancer , 2008, The EMBO journal.

[2]  J. Kirkwood,et al.  Next generation of immunotherapy for melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  Bernard Roizman,et al.  STAT1 is overexpressed in tumors selected for radioresistance and confers protection from radiation in transduced sensitive cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[4]  R. Schreiber,et al.  Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.

[5]  J. Casanova,et al.  Novel STAT1 Alleles in Otherwise Healthy Patients with Mycobacterial Disease , 2006, PLoS genetics.

[6]  David E Levy,et al.  STAT1 acts as a tumor promoter for leukemia development. , 2006, Cancer cell.

[7]  L. Hennighausen,et al.  Cre-mediated gene deletion in the mammary gland. , 1997, Nucleic acids research.

[8]  H. Kantarjian,et al.  First‐line therapy for chronic myeloid leukemia: Past, present, and future , 2009, American journal of hematology.

[9]  Robert D. Cardiff,et al.  Insights from transgenic mouse models of ERBB2-induced breast cancer , 2007, Nature Reviews Cancer.

[10]  R. Schreiber,et al.  Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway , 1996, Cell.

[11]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[12]  E. Bröcker,et al.  Effects of systemic interferon-alpha (IFN-alpha) on the antigenic phenotype of melanoma metastases. EORTC melanoma group cooperative study No. 18852. , 1993, Melanoma research.

[13]  G. Lesinski,et al.  The antitumor effects of IFN-α are abrogated in a STAT1-deficient mouse , 2003 .

[14]  P. Kuo,et al.  Osteopontin regulates ubiquitin-dependent degradation of Stat1 in murine mammary epithelial tumor cells. , 2007, Neoplasia.

[15]  D. Levy,et al.  Targeted Disruption of the Mouse Stat1 Gene Results in Compromised Innate Immunity to Viral Disease , 1996, Cell.

[16]  Paul J. Hertzog,et al.  Type I Interferon Receptors: Biochemistry and Biological Functions* , 2007, Journal of Biological Chemistry.

[17]  Steven M. Holland,et al.  Impairment of Mycobacterial But Not Viral Immunity by a Germline Human STAT1 Mutation , 2001, Science.

[18]  D. Tough,et al.  Links between innate and adaptive immunity via type I interferon. , 2002, Current opinion in immunology.

[19]  T. Eisen,et al.  Immunotherapeutic strategies in kidney cancer—when TKIs are not enough , 2009, Nature Reviews Clinical Oncology.

[20]  Hemant Ishwaran,et al.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.